



April 2025 exceptional surveillance of diabetes in pregnancy: management from preconception to the postnatal period (NICE guideline NG3)

Surveillance report

Published: 30 April 2025

www.nice.org.uk

In April 2025, we reviewed this guideline in relation to hybrid closed loop systems (HCLs) for pregnant populations with type 1 diabetes (T1D).

Surveillance decision

We will update the guideline to include <u>recommendations from NICE's technology appraisal</u> guidance on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.

The update will also focus:

April 2025 exceptional surveillance of diabetes in pregnancy: management from preconception to the postnatal period (NICE guideline NG3)

- whether to specifically recommend HCLs that are licensed for pregnant populations compared with 'off-the-shelf' HCLs for the general population, as the first line treatment for managing T1D in pregnancy.
- the benefit-risk balance of operating HCLs in pregnancy with a lower time in range (TiR) threshold of 3.5 mmol/L blood glucose compared with the currently recommended 4 mmol/L, measured using the capillary method.